Real-World Data Affirms Next-Gen TAVR Device Advantage
PHOENIX — The newer generation Evolut transcatheter aortic valve replacement (TAVR) device improved on procedural and possibly safety characteristics, the TVT registry showed. The Evolut FX device reduced need for device repositioning and cut procedure time, without a change in valve hemodynamics, at 30 days compared with the Evolut Pro+ device, reported Wah Wah Htun, […]